Hubbry Logo
NorgestrelNorgestrelMain
Open search
Norgestrel
Community hub
Norgestrel
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Norgestrel
Norgestrel
Norgestrel
View on Wikipedia
from Wikipedia

Norgestrel
Top, levonorgestrel (CAS 797-63-7 );
Bottom: dextronorgestrel (CAS 797-64-8 ).
Clinical data
Trade namesOpill, others
Other namesdl-Norgestrel; DL-Norgestrel; (±)-Norgestrel; WY-3707; SH-70850; SH-850; FH 122-A; rac-13-Ethyl-17α-ethynyl-19-nortestosterone; rac-13-Ethyl-17α-ethynylestr-4-en-17β-ol-3-one
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa602008
License data
Routes of
administration		By mouth
Drug classProgestin
ATC code
Legal status
Legal status
Identifiers
  • (8R,9S,10R,13S,14S)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.026.758 Edit this at Wikidata
Chemical and physical data
FormulaC21H28O2
Molar mass312.453 g·mol−1
3D model (JSmol)
  • O=C\1CC[C@H]4C(=C/1)/CC[C@@H]3[C@@H]4CC[C@@]2(CC)[C@H]3CCC2(O)C#C
  • InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21?/m0/s1 checkY
  • Key:WWYNJERNGUHSAO-CULCCENASA-N checkY
  (verify)

Norgestrel, sold under the brand name Opill among others, is a progestin which is used in birth control pills. It is often combined with the estrogen ethinylestradiol, marketed as Ovral. It is also used in menopausal hormone therapy.[3][4][5][6][7] It is taken by mouth.[5][6]

Side effects of norgestrel include menstrual irregularities, headaches, nausea, and breast tenderness.[8] The most common side effects of the norgestrel include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps, or bloating.[2] Norgestrel is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[6] It has weak androgenic activity and no other important hormonal activity.[6]

Norgestrel was patented in 1961 and came into medical use, specifically in birth control pills, in 1966.[9][10][11] It was subsequently introduced for use in menopausal hormone therapy as well.[7] Norgestrel is sometimes referred to as a "second-generation" progestin.[12] It is marketed widely throughout the world.[7][4] Norgestrel is available as a generic medication.[13] In 2022, the version with ethinylestradiol was the 264th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[14][15] In July 2023, the US Food and Drug Administration (FDA) approved norgestrel for over-the-counter sale.[2]

Medical uses

[edit]

Norgestrel is used in combination with ethinylestradiol or quinestrol in combined birth control pills, alone in progestogen-only birth control pills, and in combination with estradiol or conjugated estrogens in menopausal hormone therapy.[7] It has also been used as an emergency contraceptive in the Yuzpe regimen.[16]

Side effects

[edit]
See also: Levonorgestrel § Side effects, and Progestin § Side effects

Pharmacology

[edit]

Pharmacodynamics

[edit]
See also: Levonorgestrel § Pharmacodynamics

Norgestrel is a progestogen, or an agonist of the progesterone receptor.[6] The biological activity of norgestrel lies in the levo enantiomer, levonorgestrel, whereas the dextro isomer is inactive.[6] As such, norgestrel is identical in its hormonal activity to levonorgestrel except that it is half as potent by weight.[6] Levonorgestrel, and by extension norgestrel, have some androgenic activity, but no estrogenic, antimineralocorticoid, or glucocorticoid activity.[6]

Relative affinities (%) of levonorgestrel and metabolites
Compound PRTooltip Progesterone receptor ARTooltip Androgen receptor ERTooltip Estrogen receptor GRTooltip Glucocorticoid receptor MRTooltip Mineralocorticoid receptor SHBGTooltip Sex hormone-binding globulin CBGTooltip Corticosteroid binding globulin
Levonorgestrel 150–162 34a, 45 0 1–8 17–75 50 0
5α-Dihydrolevonorgestrel 50 38a 0 ? ? ? ?
3α,5α-Tetrahydrolevonorgestrel ? ? 0.4 ? ? ? ?
3β,5α-Tetrahydrolevonorgestrel ? ? 2.4 ? ? ? ?
Notes: Values are percentages (%). Reference ligands (100%) were promegestone for the PRTooltip progesterone receptor, metribolone (a = mibolerone) for the ARTooltip androgen receptor, E2 for the ERTooltip estrogen receptor, DEXATooltip dexamethasone for the GRTooltip glucocorticoid receptor, aldosterone for the MRTooltip mineralocorticoid receptor, DHTTooltip dihydrotestosterone for SHBGTooltip sex hormone-binding globulin, and cortisol for CBGTooltip Corticosteroid-binding globulin. Sources: See template.

The ovulation-inhibiting dose of norgestrel appears to be greater than 75 μg/day, as ovulation occurred in 50 to 75% of cycles with this dosage of norgestrel in studies.[17] The ovulation-inhibiting dosage of levonorgestrel, which is twice as potent as norgestrel, is approximately 50 to 60 μg/day.[6][18][17] One review lists the ovulation-inhibiting dose of norgestrel as 100 μg/day.[19] The endometrial transformation dose of norgestrel is listed as 12 mg per cycle and the menstrual delay test dose of norgestrel is listed as 0.5 to 2 mg/day.[19][20]

Pharmacokinetics

[edit]
See also: Levonorgestrel § Pharmacokinetics

The pharmacokinetics of norgestrel have been reviewed.[21]

Chemistry

[edit]
See also: List of progestogens, List of androgens/anabolic steroids, and Levonorgestrel

Norgestrel, also known as rac-13-ethyl-17α-ethynyl-19-nortestosterone or as rac-13-ethyl-17α-ethynylestr-4-en-17β-ol-3-one, is a synthetic estrane steroid and a derivative of testosterone.[3][4] It is a racemic mixture of stereoisomers dextronorgestrel (the C13α isomer; l-norgestrel, L-norgestrel, or (+)-norgestrel) and levonorgestrel (the C13β isomer; d-norgestrel, D-norgestrel, or (–)-norgestrel), the former of which is inactive (making norgestrel exactly half as potent as levonorgestrel).[22][23] Norgestrel is more specifically a derivative of norethisterone (17α-ethynyl-19-nortestosterone) and is a member of the gonane (18-methylestrane) subgroup of the 19-nortestosterone family of progestins.[24]

Synthesis

[edit]

Chemical syntheses of norgestrel have been published.[21]

History

[edit]

Norgestrel was first introduced, as a birth control pill in combination with ethinylestradiol, under the brand name Eugynon in Germany in 1966.[9][10] It was subsequently marketed as a combined birth control pill with ethinylestradiol in the United States under the brand name Ovral in 1968, and was marketed in many other countries as well.[25][26][7]

The contraceptive efficacy of norgestrel was established in the U.S. with the original approval for prescription use in 1973.[2]

In July 2023, the FDA approved norgestrel for over-the-counter sale.[2][27] The FDA granted the approval to Laboratoire HRA Pharma which was acquired by Perrigo Company plc.[2]

Society and culture

[edit]

Generic names

[edit]

Norgestrel is the generic name of the drug and its international nonproprietary name, United States Adopted Name, United States Pharmacopeia, British Approved Name, Dénomination Commune Française, Denominazione Comune Italiana, and Japanese Accepted Name.[3][4][5][7] It is also known as dl-norgestrel, DL-norgestrel, or (±)-norgestrel.[3][4][5][7]

Brand names

[edit]

Norgestrel is marketed under a variety of brand names including Cyclacur, Cryselle, Cyclo-Progynova, Duoluton, Elinest, Eugynon, Microgynon, Lo/Ovral, Low-Ogestrel, Logynon, Microlut, Minicon, Nordette, Neogest, Opill, Ogestrel, Ovral, Ovran, Ovranette, Ovrette, Planovar, Prempak, Progyluton, and Trinordiol among others.[3][4][7][25]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Norgestrel

View on Grokipedia
from Grokipedia
Norgestrel is a synthetic progestin employed primarily as a progestin-only oral contraceptive to prevent . It functions by suppressing , thickening cervical to impede transport, and potentially altering the endometrial lining to deter implantation. Chemically, norgestrel constitutes a of two enantiomers: , which exhibits the progestogenic activity, and dextronorgestrel, which is pharmacologically inert. Originally approved by the U.S. (FDA) in 1973 for prescription use in contraception, norgestrel has been available in formulations such as 0.075 mg tablets, demonstrating high efficacy with typical use failure rates around 9% annually due to adherence challenges inherent to daily dosing. In July 2023, the FDA granted approval for over-the-counter sales of norgestrel under the brand Opill, marking the first nonprescription daily oral contraceptive in the United States and enhancing accessibility without requiring medical consultation. As a second-generation progestin, it binds to progesterone receptors with high affinity, mimicking endogenous progesterone effects while lacking significant estrogenic or androgenic activity, which contributes to its tolerability profile in users. Norgestrel's development stemmed from efforts to create potent synthetic progestogens for reliable control, with its contraceptive efficacy validated through clinical studies establishing inhibition as the primary mechanism even at low doses. While effective, its use is contraindicated in conditions such as active thromboembolic disorders or undiagnosed , reflecting standard risks associated with progestin-based therapies. The shift to over-the-counter status addresses barriers to reproductive access, though ongoing monitoring for side effects like irregular or mood alterations remains essential.

Medical Applications

Contraceptive Indications

Norgestrel is utilized in progestin-only oral contraceptives (POPs) specifically for the prevention of , administered as a daily tablet containing 0.075 mg of the synthetic progestin without an component. This formulation, exemplified by products like Opill, requires continuous intake at the same time each day to sustain contraceptive effects, with no scheduled pill-free intervals, accommodating users such as lactating women or those intolerant to estrogens. The primary contraceptive mechanisms of norgestrel at this dose encompass suppression of in roughly half of cycles through disruption of follicular growth and release, alongside production of thick, viscous that reduces and penetration, and modification of the endometrial lining to impair implantation. Clinical evaluations, including ultrasound-monitored cycle studies and scoring assessments, confirm these actions persist across the 28-day cycle, even in ovulatory cycles where remains hostile to . In contrast to combined estrogen-progestin pills, which predominantly rely on consistent inhibition via dual hormonal action, norgestrel POPs emphasize progestin-driven cervical and endometrial barriers as complementary safeguards, particularly in cycles where occurs. This progestin-only approach is not approved or recommended for post-coital contraception, unlike regimens that employ higher single or split doses for that purpose.

Non-Contraceptive Uses

Norgestrel, typically administered in combination with ethinyl , has been applied clinically to manage dysfunctional uterine (DUB) and associated menstrual irregularities through its endometrial stabilizing effects, which promote cessation of excessive hemorrhage and restoration of cyclic function. A 1976 prospective study of 44 patients presenting with spasmodic , DUB, or menorrhagia employed an initial regimen of 1.5–2 mg norgestrel (with 0.15–0.2 mg ethinyl ) daily—divided into 3–4 doses—until halted, followed by standard cyclic dosing of one tablet daily for 21 days with a 7-day interruption; this yielded complete symptom resolution in all dysmenorrhea cases, normalized endometrial via in bleeding disorders, and overall high tolerability with minimal adverse reports. Acute protocols for have included 1.2 mg norgestrel (with 120 μg ethinyl ) daily in divided doses until , as outlined in algorithms for . For ongoing control of DUB or , daily oral dosing of 0.75 mg norgestrel monotherapy has been documented in clinical references, leveraging its progestogenic potency to suppress endometrial proliferation and reduce blood loss volume. Similarly, in menorrhagia, norgestrel-containing combined formulations are noted for efficacy in endometrial stabilization, outperforming less potent progestins in preventing breakthrough hemorrhage. Norgestrel's role extends to endometriosis symptom palliation, where its administration at 0.75 mg daily aids in suppressing ectopic endometrial growth and associated by inducing endometrial . These applications, however, remain secondary to its primary contraceptive indications, with supporting data largely from mid-20th-century trials and pharmacological overviews rather than large randomized controlled trials specific to norgestrel alone.

Efficacy

Clinical Effectiveness Data

Norgestrel, at a dose of 75 μg daily in progestin-only pills (POPs), exhibits a median of 1.73 pregnancies per 100 woman-years across clinical studies, with a range of 0.00 to 9.00.00448-6/fulltext) This metric primarily captures perfect use efficacy, where adherence is strict, yielding failure rates of approximately 1-2% annually in low-bias trials. Typical use failure rates, accounting for common adherence lapses, are estimated at 9% in the first year, though aggregated data from recent reviews suggest actual observed rates may be lower, around 3-7%. A 2021 systematic review of norgestrel 75 μg/day use documented 53 pregnancies among participants, with 26 occurring during perfect use, affirming its high comparable to combined oral contraceptives under ideal conditions.00375-9/fulltext) remains consistent across and non-breastfeeding women, with no significant differences in failure estimates between these groups. Relative to other POPs like (75 μg), norgestrel demonstrates superior tolerance for dosing variability due to its longer elimination of 17-19 hours, permitting delays up to 6 hours without elevating risk—unlike desogestrel's stricter 3-hour window. This pharmacokinetic advantage contributes to norgestrel's marginally higher real-world among POP formulations.00448-6/fulltext)

Factors Influencing Performance

Adherence to the daily dosing schedule is a primary determinant of norgestrel's contraceptive performance, as its short requires consistent intake within a narrow window to sustain inhibitory effects on . Delays exceeding three hours from the usual time necessitate immediate intake of the missed dose followed by backup contraception, such as barrier methods, for the subsequent 48 hours to mitigate failure risk. Empirical studies simulating real-world use demonstrate that self-reported adherence rates above 85% correlate with maintained , underscoring how lapses in routine—often due to forgetfulness or disruptions—elevate pregnancy probabilities through inconsistent hormone levels. Gastrointestinal events like or severe occurring within three to four hours post-dose can impair absorption, effectively mimicking a missed dose and requiring supplemental protection until the next scheduled intake confirms resumption. Drug interactions further modulate performance, particularly with hepatic enzyme inducers such as , , or rifampin, which accelerate norgestrel metabolism via pathways, thereby reducing circulating levels and contraceptive reliability; users on these medications should employ alternative methods. User demographics influence compliance rather than intrinsic for norgestrel, with no indicating significant efficacy diminishment from short delays in reproductive-age women across BMI ranges, though may indirectly heighten discontinuation via side effect intolerance. Breastfeeding status does not compromise performance, as progestin-only formulations like norgestrel maintain suppression without affecting production or safety. Age-related factors, such as perimenopausal inconsistencies, can affect adherence but not the drug's mechanism when dosed properly. In contrast to , norgestrel's pill form amplifies vulnerability to , yet exhibits lower typical-failure rates than non-hormonal behavioral methods like condoms, where inconsistent application drives higher incidences. Bleeding irregularities, including unscheduled spotting common in the initial months of progestin-only use, represent a verifiable cause of dropout, prompting method switches in users intolerant to cycle disruptions absent in non-user-dependent options.

Adverse Effects and Risks

Common Side Effects

The most frequently reported adverse reactions to norgestrel, particularly in progestin-only formulations such as the 0.075 mg daily tablet, are menstrual irregularities including breakthrough bleeding, spotting, and changes in menstrual flow or duration. These effects arise from progestin-induced endometrial changes and affect up to 70% of users with breakthrough bleeding or spotting in one or more cycles, though incidence often decreases after the first few months of continuous use. Additional common short-term side effects include headaches, , breast tenderness, , increased , and abdominal cramps or , which are generally mild and self-limiting. Clinical data from users indicate these symptoms typically manifest early in treatment and resolve without intervention in most cases, distinguishing them from rarer, persistent issues.

Serious Adverse Events

Use of norgestrel in progestin-only oral contraceptives is not associated with a significantly elevated risk of venous thromboembolism (VTE), unlike combined estrogen-progestin formulations, where VTE incidence ranges from 7-10 per 10,000 woman-years. Epidemiological data indicate that low-dose oral progestins maintain VTE rates comparable to non-users, with relative risks near 1.0 in multiple cohort studies. Contraceptive failure with norgestrel, which occurs in approximately 7-9% of typical users annually, carries an elevated risk of compared to intrauterine pregnancies, attributable to progestins' inhibition of oviductal motility and altered implantation dynamics. Among pregnancies in progestin-only pill users, ectopic rates can reach up to 10-15%, versus 1-2% in the general ; symptoms include severe and spotting, necessitating prompt evaluation. Norgestrel is contraindicated in individuals with active or prior due to progestins' potential to stimulate hormone-sensitive tumors, as evidenced by observational data showing slightly increased breast cancer incidence during use (relative risk 1.2-1.5). Similarly, severe hepatic impairment or undiagnosed precludes use, with post-marketing reports linking progestins to rare cholestatic or exacerbation of bleeding sources. Severe reactions, including , have been documented in isolated cases, manifesting as , wheezing, or facial ; immediate discontinuation is required. While risk remains unincreased relative to non-users, monitoring is advised in predisposed individuals, as progestins may contribute to fluid retention in rare instances.

Long-Term Health Considerations

Long-term use of norgestrel, a synthetic progestin primarily exerting effects through its , has been linked to elevated risk in cohort studies and of progestogen-containing contraceptives. A 2023 UK nested case-control study and reported a increase of 20% to 30% for among current or recent users of hormonal contraceptives, with similar associations observed for progestogen-only formulations comparable to norgestrel. This risk persists for up to 5 years post-discontinuation and aligns with findings from levonorgestrel-based methods, where ever-use of intrauterine systems showed a 26% relative increase. Absolute risks are modest given low baseline incidence in premenopausal women, typically adding 1 to 2 cases per 10,000 woman-years of use among those aged 16-49, though cumulative exposure amplifies incidence without offsetting reductions in overall cancer mortality observed in large registries. Regarding , discontinuation of norgestrel-based oral contraceptives does not appear to delay return to , with meta-analyses of progestin users showing rates of 77% to 86% within 12 months, comparable to non-users. Specific trials with low-dose equivalents confirmed no significant postponement, as resumes promptly and endometrial recovery supports conception timelines akin to baseline . density effects from prolonged norgestrel exposure are minimal and reversible, differing from depot progestins like ; prospective data on analogous implants and systems indicate no sustained loss at the lumbar spine or after 18-24 months, with accrual resuming post-cessation in adolescents and adults. Metabolic impacts from extended norgestrel use include modest elevations in triglycerides and HDL , with variable LDL effects across progestins, but no consistent progression to or in meta-analyses of oral formulations. These changes lack causal links to long-term cardiovascular events in observational cohorts, though absolute risk increments—such as 5-10% higher triglycerides versus non-users—warrant monitoring in predisposed individuals, without evidence of net mortality benefits from widespread adoption offsetting these exposures. Overall, while risks are small in absolute terms, cohort-derived relative elevations underscore the need for individualized assessment over assumptions of neutrality in prolonged regimens.

Pharmacology

Pharmacodynamics

Norgestrel, a of and dextronorgestrel, exerts its progestogenic effects exclusively through the biologically active levorotatory , , which serves as a potent agonist of the (PR). demonstrates high-affinity binding to the PR, with relative binding affinities (RBA) reported as 125% to PR, 143% to human uterine PR, and up to 323% relative to progesterone in human steroid receptor assays. This binding induces conformational changes in the PR, promoting dimerization and of target genes that mediate progestational responses, including endometrial transformation and inhibition of follicular development. The primary physiological downstream effect involves antigonadotropic activity: binding to PR in hypothalamic and pituitary tissues suppresses (GnRH) pulsatility, thereby reducing secretion of (FSH) and (LH), which prevents the mid-cycle LH surge essential for . Due to norgestrel's racemic composition, where dextronorgestrel shows no appreciable binding or activity at the PR or other steroid receptors, the effective progestogenic potency of norgestrel is roughly equivalent to half the administered dose when compared to pure . Levonorgestrel also displays moderate affinity for the (AR), with an RBA of approximately 58% relative to , conferring weak androgenic agonism that can influence activity and protein anabolism but at lower potency than its progestogenic effects. It exhibits negligible estrogenic activity but antiestrogenic properties in certain contexts, such as opposing estrogen-induced endometrial proliferation, though weaker overall than its PR-mediated actions. Binding to (GR, RBA ~7.5%) and (MR, RBA ~17%) receptors is minimal, distinguishing norgestrel from progestins like that show greater and associated metabolic effects.

Pharmacokinetics

Norgestrel is rapidly absorbed following , with peak serum progestin levels occurring about 2 hours after dosing, followed by rapid distribution. Its is approximately 90%, indicating minimal first-pass effect and efficient systemic uptake. Plasma concentrations decline bi-exponentially, reflecting distribution into tissues and subsequent elimination. The elimination of norgestrel in plasma is approximately 15 to 17 hours, supporting once-daily dosing with some flexibility for timing variations. Steady-state levels are typically reached after 1 to 2 weeks of continuous daily administration, due to enterohepatic recirculation which prolongs exposure by recycling conjugated metabolites. Norgestrel undergoes primary hepatic via 3A4 () enzymes, forming hydroxylated metabolites that are subsequently conjugated to glucuronides and sulfates. Excretion occurs mainly as metabolites, with about 43% eliminated in urine over 5 days and the remainder via feces, including through biliary routes. Relative to other progestin-only pills like those containing norethisterone ( ~8 hours), norgestrel's extended contributes to sustained plasma levels, reducing the immediacy of risk after a missed dose.

Chemistry

Chemical Properties and Structure


Norgestrel is a synthetic progestin with the molecular formula C₂₁H₂₈O₂ and a molecular weight of 312.45 g/mol. It exists as a racemic mixture of two enantiomers: dextronorgestrel (the inactive (+)-form) and levonorgestrel (the active (-)-eutomer). The core structure is a 18,19-dinorpregna-4-en-3-one gonane derivative featuring a 13-ethyl substituent, a 17α-ethynyl group, a 17β-hydroxy group, and a Δ¹⁵ double bond. This configuration distinguishes it from norethindrone, from which it is derived by replacing the 13-methyl group with an ethyl group, altering its steric properties and bioactivity.
The IUPAC name for the levonorgestrel enantiomer is (8R,9R,10R,13S,14R,17R)-13-ethyl-17-ethynyl-17-hydroxy-18,19-dinorpregna-4,15-diene-3-one. Norgestrel's lipophilic nature is evidenced by a predicted octanol-water partition coefficient (logP) of 3.25–3.66, promoting passive diffusion across lipid membranes. Its aqueous solubility is low, approximately 0.006 mg/mL at physiological pH, classifying it as practically insoluble in water and requiring pharmaceutical formulations like micronized powders or lipid-based vehicles for oral bioavailability.
Norgestrel demonstrates chemical stability under physiological conditions, with no readily hydrolyzable functional groups, enabling intact absorption from the gastrointestinal tract following oral administration. This stability is critical for its formulation in tablets, where it resists degradation in acidic environments without significant excipient interactions under standard storage.

Synthesis Methods

Norgestrel, as a of and dextronorgestrel, is synthesized industrially through the ethynylation of the 17-keto precursor dl-13-ethyl-18,19-dinor-17-oxogon-4-en-3-one. This key step employs acetylide reagents such as ethynylmagnesium or acetylide-ethylenediamine complex, followed by acidic workup to introduce the 17α-ethynyl-17β-hydroxy functionality with retention of the racemic at C13 and C17. The process, originally developed by Laboratories in the early through total routes culminating in this addition, achieves yields of approximately 60-80% for the ethynylation under optimized conditions, enabling scalable production for pharmaceutical use. The precursor 17-keto steroid itself is prepared via multi-step degradation and sequences from basic steroid building blocks like , involving angular methyl removal at C18 and C19, followed by ethylation at C13 to introduce the characteristic ethyl substituent enhancing progestational potency. Early patents, such as those filed in 1963, describe these transformations using microbial or chemical demethylation and Grignard-type alkylations, with overall process yields supporting commercial viability despite the complexity. Modern laboratory adaptations for norgestrel maintain the racemic form but incorporate improvements like one-pot ethynylation-desilylation using and catalytic desilylation agents to mitigate steric hindrance from the 13-ethyl group, which traditionally lowers reactivity of the 17-keto carbonyl. These enhancements boost step yields to over 85% and reduce byproducts, though industrial production retains the classical acetylide method for cost efficiency, as resolution to enantiopure is unnecessary for norgestrel formulations. Alternative routes starting from intermediates via acetylide addition have been explored for related compounds but are less common for the dl-racemate due to scalability challenges in ethyl introduction.

History

Development and Discovery

Norgestrel, a synthetic 19-nortestosterone-derived progestin, was developed in the early 1960s as part of pharmaceutical efforts to create more potent analogs for oral contraception. The compound emerged from research aimed at improving upon first-generation progestins, with synthesis occurring between 1960 and 1965 through a collaborative effort between Wyeth Laboratories in the United States and Schering AG in Germany. This partnership focused on producing orally active steroids with strong progestational effects to suppress ovulation and alter endometrial receptivity more effectively than prior agents. Preclinical evaluations in animal models, including rabbits and rodents, confirmed norgestrel's high progestational potency, as measured by assays such as the Clauberg test for endometrial transformation. These studies revealed activity superior to earlier compounds like norethindrone, owing to structural enhancements that amplified binding affinity to progesterone receptors while maintaining oral . Compared to norethynodrel—the progestin in the inaugural combined oral contraceptive Enovid—norgestrel demonstrated greater in inhibiting estrogen-induced endometrial proliferation at lower doses, reducing the required amount for contraceptive applications. Initial toxicity assessments also indicated a favorable safety profile in non-human primates, supporting progression to formulations combining norgestrel with estrogens like ethinyl estradiol for synergistic suppression. The foundational research transitioned norgestrel from laboratory synthesis to early contraceptive prototypes, initially emphasizing combined regimens to mimic natural hormonal cycles. By the mid-1960s, preclinical data underscored its potential for progestin-only uses, foreshadowing standalone pills that relied solely on its antigonadotropic and cervical mucus-thickening properties without estrogenic components. This shift addressed concerns over estrogen-related side effects observed in earlier combined pills.

Key Milestones and Approvals

The U.S. (FDA) first approved norgestrel for prescription use in a progestin-only oral contraceptive in 1973, marketed under the brand name Ovrette at a dose of 0.075 mg daily. This marked the initial regulatory milestone for norgestrel as a standalone contraceptive agent in the United States, establishing its efficacy in preventing and altering cervical to inhibit sperm penetration. Combined oral contraceptives containing norgestrel and ethinyl estradiol, such as Ovral (0.5 mg norgestrel/50 mcg ethinyl estradiol), received FDA approval in the late 1960s to early 1970s, enabling broader commercial availability for cycle control and pregnancy prevention. By the 1980s, norgestrel-based progestin-only pills (POPs) achieved widespread global adoption in initiatives, particularly in developing regions, where they contributed to expanded access for women seeking estrogen-free options due to contraindications like or vascular risks. Population-level studies from the 1970s and 1980s documented correlations between increased POP adoption, including norgestrel formulations, and declines in rates; for instance, in cohorts with consistent use, typical-use failure rates ranged from 3-9%, lower than barrier methods, supporting causal links to reduced and birth rates in monitored programs. These advancements aligned with international endorsements, though norgestrel itself was not separately listed on the WHO Model List of , which prioritized related progestins like for contraceptive management starting in the .

Recent Regulatory Changes

In July 2023, the U.S. (FDA) approved Opill (0.075 mg norgestrel tablet) for nonprescription use as the first daily oral contraceptive available over-the-counter (OTC) in the United States to prevent . This decision was based on clinical trials and actual-use studies demonstrating that consumers aged 15 and older could self-select, understand labeling, and adhere to the product without professional supervision, with efficacy rates of approximately 98% under typical use conditions and no identified increases in adverse events compared to prescription access. Opill launched for OTC sale across U.S. pharmacies, retailers, and platforms in March 2024, expanding access without requiring a healthcare provider visit or prescription. Post-approval monitoring and reviews through 2025 have reaffirmed norgestrel's safety profile in nonprescription settings, including data from switch studies showing sustained adherence and low misuse rates, with failure rates aligning with prior prescription data (around 7% typical use, <1% perfect use). Internationally, norgestrel maintains generic availability in and select developing markets as a progestin-only option, with regulatory frameworks unchanged since 2020 permitting over-the-counter or pharmacy access in countries like the and parts of the , though no widespread reevaluations or expansions occurred in this period.

Society and Culture

Nomenclature and Branding

Norgestrel is the established , as designated by the , along with its (USAN), (BAN), and Japanese Accepted Name (JAN). It is also recognized under the (USP) monograph standards. The compound is frequently referred to by synonyms such as d,l-norgestrel or dl-norgestrel, reflecting its racemic nature as a 1:1 mixture of the active levorotatory (levonorgestrel) and the inactive dextrorotatory (dextronorgestrel). This distinction is pharmacologically significant, as exhibits approximately twice the progestational potency of the racemate due to the inactivity of the dextronorgestrel component, which contributes minimal therapeutic benefit and potential side effects without enhancing efficacy. Commercially, norgestrel is branded as Opill in its progestin-only formulation (0.075 mg tablets), approved by the U.S. for over-the-counter use. In combined oral contraceptives, it appears under historical brands such as Ovral (with ethinyl estradiol), alongside generic equivalents like Low-Ogestrel or Cryselle. These identifiers facilitate precise pharmaceutical referencing, with no substantial linguistic variations reported in major non-English markets beyond standardized INN transliterations.

Availability and Market Status

In the United States, norgestrel is marketed over-the-counter as Opill, a progestin-only daily oral contraceptive providing 0.075 mg per tablet in 28-day packs, with options for 1-month ($19.99), 3-month ($49.99), and 6-month ($89.99) supplies available at major retailers, pharmacies, and online. The U.S. approved its switch to OTC status in July 2023, with nationwide availability beginning in March 2024, eliminating prescription barriers for all ages. Globally, norgestrel formulations, often in combined oral contraceptives, remain predominantly prescription-only, though regulatory status varies; generic equivalents of products like Low-Ogestrel (norgestrel with ethinyl estradiol) are widely produced, enabling cost reductions through competition and bulk procurement. Branded combined variants such as Lo/Ovral have faced discontinuation in certain markets, with manufacturers shifting to generics to maintain supply. In low-resource settings, distribution relies on international aid and supply chains, including programs by the that procure and deliver hormonal contraceptives to reduce dependency on commercial markets. Post-OTC transition in the U.S., empirical data show enhanced access, with over 25% of Opill users reporting a switch from no prior contraceptive method, correlating with broader uptake trends.

Debates and Criticisms

The approval of norgestrel as an over-the-counter (OTC) progestin-only pill on , 2023, has sparked over balancing against the challenges of self-screening for contraindications. Proponents argue that OTC availability enhances equity by reducing barriers for underserved populations, with studies indicating that 98% of potential users can appropriately self-select the product based on labeling, minimizing misuse. Critics, however, highlight risks of inadequate self-monitoring for conditions such as undiagnosed , , or , where improper use could exacerbate health issues without medical oversight; while such misuse appears rare in simulated self-selection trials, real-world data on nonprescription progestins underscore the potential for lower efficacy and undetected contraindications compared to supervised prescription use. Public health messaging on norgestrel and similar hormonal methods has faced criticism for underemphasizing long-term implications, including temporary delays in fertility return after discontinuation—observed in some cohorts using progestogen-only pills prior to planned pregnancies—and the higher absolute risks accrued by young users initiating daily regimens early in reproductive years. Although empirical evidence confirms no permanent infertility from progestin-only contraceptives, concerns persist that campaigns prioritize short-term convenience and efficacy (e.g., 91-98% typical use effectiveness when adherent) over counseling on postponement effects, which may influence reproductive decision-making amid rising awareness of age-related fertility declines. From pro-natalist viewpoints, the promotion of accessible hormonal options like norgestrel contributes to broader demographic shifts by enabling prolonged deferral, correlating with sharp declines in developed nations following the introduction of contraceptives, where total rates fell below replacement levels amid rapid pill adoption. Advocates for counter that such methods empower intentional childbearing, reducing unintended pregnancies and supporting smaller, planned families; nonetheless, these perspectives often contrast with non-hormonal alternatives like barrier methods or periodic , which avoid systemic risks and appeal to users prioritizing minimal intervention or natural cycles. Religious and conservative critiques further question hormonal contraception's alignment with pro-life principles, viewing or post-coital uses (possible at higher norgestrel doses) as blurring lines with mechanisms, though attributes primary action to inhibition rather than post-fertilization effects.

References

  1. https://medlineplus.gov/druginfo/meds/a623039.html
  2. https://www.mayoclinic.org/drugs-supplements/norgestrel-oral-route/description/drg-20552473
  3. https://pubchem.ncbi.nlm.nih.gov/compound/norgestrel
  4. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/opill-0075mg-oral-norgestrel-tablet-information
  5. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive
  6. https://go.drugbank.com/drugs/DB09389
  7. https://pubmed.ncbi.nlm.nih.gov/35367204/
  8. https://my.clevelandclinic.org/health/drugs/18974-norgestrel-tablets-contraception
  9. https://reference.medscape.com/drug/opill-norgestrel-342790
  10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017031s035s036lbl.pdf
  11. https://www.cdc.gov/contraception/hcp/usspr/progestin-only-pills.html
  12. https://www.sciencedirect.com/science/article/pii/S0010782422000798
  13. https://pubmed.ncbi.nlm.nih.gov/4557273/
  14. https://www.ncbi.nlm.nih.gov/books/NBK608186/
  15. https://pubmed.ncbi.nlm.nih.gov/12306340/
  16. https://www.jabfm.org/content/jabfp/19/6/590.full.pdf
  17. https://www.sciencedirect.com/topics/medicine-and-dentistry/norgestrel
  18. https://www.clinician.com/articles/the-progestin-only-pill-how-effective-is-it
  19. https://pubmed.ncbi.nlm.nih.gov/36535414/
  20. https://www.sciencedirect.com/science/article/pii/S0010782421003759
  21. https://www.sciencedirect.com/science/article/pii/S0010782422004486
  22. https://www.webmd.com/drugs/2/drug-188275/opill-oral/details
  23. https://www.sciencedirect.com/science/article/pii/S0010782424000349
  24. https://www.webmd.com/drugs/2/drug-63881/cryselle-28-oral/details
  25. https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.norgestrel-0-075-mg-tablet.194696
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC11957599/
  27. https://www.sciencedirect.com/science/article/abs/pii/S1751485124000266
  28. https://publications.aap.org/pediatrics/article/134/4/e1244/32981/Contraception-for-Adolescents
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC4944814/
  30. https://www.ccjm.org/content/90/3/181
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC12206558/
  32. https://pubmed.ncbi.nlm.nih.gov/8982741/
  33. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017031s041lbl.pdf
  34. https://www.sciencedirect.com/science/article/abs/pii/S0049384812000904
  35. https://ashpublications.org/hematology/article/2024/1/644/526191/Estrogen-progestin-and-beyond-thrombotic-risk-and
  36. https://www.news-medical.net/health/Advantages-and-Disadvantages-of-the-Progestogen-Only-Pill-%28POP%29.aspx
  37. https://www.acog.org/womens-health/faqs/progestin-only-hormonal-birth-control-pill-and-injection
  38. https://www.drugs.com/drug-interactions/norgestrel.html
  39. https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet
  40. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=303264da-c919-e0ce-e063-6394a90a4cc7&type=display
  41. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004188
  42. https://academic.oup.com/jnci/article/117/5/1046/7951389
  43. https://www.nejm.org/doi/full/10.1056/NEJMoa1700732
  44. https://www.contraceptionjournal.org/article/S0010-7824%2811%2900161-2/abstract
  45. https://pubmed.ncbi.nlm.nih.gov/18462723/
  46. https://academic.oup.com/humrep/article/21/2/466/614188
  47. https://pubmed.ncbi.nlm.nih.gov/33048062/
  48. https://pubmed.ncbi.nlm.nih.gov/28732568
  49. https://pubmed.ncbi.nlm.nih.gov/37178/
  50. https://www.sciencedirect.com/science/article/pii/001078249400019S
  51. https://www.clinpgx.org/drug/PA450218
  52. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/norgestrel
  53. https://go.drugbank.com/drugs/DB00367
  54. https://www.ncbi.nlm.nih.gov/books/NBK563211/
  55. https://www.tocris.com/products/levonorgestrel_4833
  56. https://www.sciencedirect.com/science/article/abs/pii/S0006291X2031799X
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC2778424/
  58. https://pubmed.ncbi.nlm.nih.gov/947291/
  59. https://www.ncbi.nlm.nih.gov/books/NBK539737/
  60. https://pubmed.ncbi.nlm.nih.gov/3121231/
  61. https://www.sciencedirect.com/topics/chemistry/norgestrel
  62. https://datasheets.scbt.com/sc-205415.pdf
  63. https://onlinelibrary.wiley.com/doi/abs/10.1002/hlca.19710540852
  64. https://pubmed.ncbi.nlm.nih.gov/19936155/
  65. https://www.researchgate.net/publication/244190356_One-pot_ethynylation_and_catalytic_desilylation_in_synthesis_of_mestranol_and_levonorgestrel
  66. https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/norgestrel
  67. https://www.drugs.com/history/opill.html
  68. https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/16672-s047_ovral_ovral-28.pdf
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC3520685/
  70. https://list.essentialmeds.org/medicines/186
  71. https://www.nejm.org/doi/full/10.1056/NEJMp2308720
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC11169152/
  73. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2024/03/first-over-the-counter-daily-contraceptive-pill-released
  74. https://www.uspharmacist.com/article/otc-daily-birth-control-pill-available-in-early-2024
  75. https://pubmed.ncbi.nlm.nih.gov/38346681/
  76. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/referral-procedures-human-medicines/combined-hormonal-contraceptives
  77. https://pubchem.ncbi.nlm.nih.gov/substance/134987052
  78. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2881
  79. https://labeling.pfizer.com/showlabeling.aspx?id=764
  80. https://www.drugs.com/ingredient/norgestrel.html
  81. https://www.drugs.com/opill.html
  82. https://opill.com/products/opill
  83. https://www.goodrx.com/low-ogestrel/what-is
  84. https://www.drugs.com/availability/generic-lo-ovral-28.html
  85. https://esaro.unfpa.org/sites/default/files/pub-pdf/2025-10/UNFPA%2520%2520-%2520Bottleneck%2520Summary%2520Report%2520V4.pdf
  86. https://www.opb.org/article/2025/08/27/over-the-counter-pill-birth-control-access-ohsu-study/
  87. https://www.sciencedirect.com/science/article/pii/S0010782424000544
  88. https://www.pharmacytimes.com/view/what-you-should-know-about-norgestrel-an-otc-birth-control-option
  89. https://academic.oup.com/humrep/article/17/10/2754/607778
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC6055351/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC10755709/
  92. https://academic.oup.com/humupd/article/12/5/603/778783
  93. https://www.usccb.org/committees/pro-life-activities/emergency-contraception-boon-or-bane
  94. https://www.npr.org/sections/health-shots/2013/02/22/172595689/morning-after-pills-dont-cause-abortion-studies-say
Add your contribution
Related Hubs
User Avatar
No comments yet.